The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 113s Year: 2004
Serum leptin levels in obstructive sleep apnoea patients Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007
Does low plasma adiponectin level affect cardiovasculer risk in obstructive sleep apnea syndrome? Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007
Serum leptin levels in obese patients with severe obstructive sleep apnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 332s Year: 2004
Serum resistin level in pediatric obstructive sleep apnea Source: Annual Congress 2008 - Paediatric respiratory epidemiology I: primary ciliary dyskinesia, sleep-disordered breathing, exercise-induced symptoms and rare diseases Year: 2008
Determinant factors of serum leptin levels in patients with obstructive sleep apnea Source: Annual Congress 2005 - Metabolic control in OSA Year: 2005
Relationship between plasma NT-proBNP level and cardiovascular complications in obstructive sleep apnoea (OSA) patients Source: Annual Congress 2010 - Nocturnal cardiology: chronic heart failure, acute chest syndrome, coronary artery disease and collagen vascular disease Year: 2010
Elevated leptin is associated with impaired glucose tolerance in obstructive sleep apnoea (OSA) Source: Eur Respir J 2006; 28: Suppl. 50, 573s Year: 2006
Differences in levels of systemic inflammation markers between obese subjects with or without obstructive sleep apnea Source: Annual Congress 2010 - Biomarkers for oxidative stress, inflammation and cardiovascular function in sleep apnoea Year: 2010
Reduced plasma fetuin-A levels in patients with obstructive sleep apnoea}, Source: Eur Respir J 2012; 40: 1046-1048 Year: 2012
Elevated serum homocysteine levels in patients with obstructive sleep apnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 566s Year: 2004
Relationship between NT-proBNP plasma level and nocturia in obstructive sleep apnoea (OSA) patients Source: Annual Congress 2007 - Systemic effects of obstructive sleep apnoea Year: 2007
Cardiovascular diseases are responsible for increased plasma NT-proBNP level in obstructive sleep apnoea (OSA) patients Source: Annual Congress 2012 - Physiology, obesity and the downstream effects of OSA Year: 2012
Investigation on serum adiponectin levels in patients with obstructive sleep apnea hypopnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 445s Year: 2004
Plasma adiponectin levels and hypoxic stress in patients with obstructive sleep apnea syndrome (OSAS) Source: Annual Congress 2004 - Systemic and metabolic effects from OSA Year: 2004
Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment Source: Eur Respir J 2003; 22: 251-257 Year: 2003
Serum levels of circulating adipocytokines, leptin and adiponectin, in obstructive sleep apnea Source: Eur Respir J 2004; 24: Suppl. 48, 692s Year: 2004
Angio-inhibitory activity and decreased leptin level in sera from obstructive sleep apnea syndrome (OSAS) patients Source: Eur Respir J 2001; 18: Suppl. 33, 334s Year: 2001
Obstructive sleep apnea and levels of physical activity and its association with elevated cardiovascular risk in chilean adults Source: International Congress 2018 – Diagnostics including questionnaires Year: 2018
Relationship between sleep apnea syndrome, plasma myeloperoxidase levels and cardiovascular risk Source: Annual Congress 2012 - Metabolic and cardiovascular consequences of OSA I Year: 2012